NASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis $24.85 -0.20 (-0.79%) As of 11:02 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Pacira BioSciences Stock (NASDAQ:PCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pacira BioSciences alerts:Sign Up Key Stats Today's Range$24.56▼$25.1550-Day Range$23.00▼$27.6252-Week Range$18.80▼$27.66Volume39,854 shsAverage Volume662,700 shsMarket Capitalization$990.61 millionP/E Ratio71.01Dividend YieldN/APrice Target$30.14Consensus RatingHold Company Overview Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies. Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief. Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies. Pacira primarily serves healthcare professionals and institutions in the United States and has pursued international commercialization through partnerships and licensing arrangements.AI Generated. May Contain Errors. Read More Pacira BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScorePCRX MarketRank™: Pacira BioSciences scored higher than 65% of companies evaluated by MarketBeat, and ranked 201st out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingPacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 4 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialPacira BioSciences has a consensus price target of $30.14, representing about 20.3% upside from its current price of $25.05.Amount of Analyst CoveragePacira BioSciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pacira BioSciences' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth23.56% Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 23.56% in the coming year, from $1.91 to $2.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 71.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 71.57, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.34.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pacira BioSciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.27% of the float of Pacira BioSciences has been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 12.98, which indicates bearish sentiment.Change versus previous monthShort interest in Pacira BioSciences has recently increased by 3.18%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.25 News SentimentPacira BioSciences has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pacira BioSciences this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for PCRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $70,619.00 in company stock.Percentage Held by Insiders6.40% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pacira BioSciences' insider trading history. Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCRX Stock News HeadlinesPacira BioSciences, Inc. (NASDAQ:PCRX) Stock Has Consensus Target Price of $30.14 According to AnalystsOctober 6 at 4:29 AM | americanbankingnews.comPacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United KingdomOctober 5 at 8:00 AM | globenewswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 6 at 1:00 AM | Porter & Company (Ad)Gyre Therapeutics (NASDAQ:GYRE) versus Pacira BioSciences (NASDAQ:PCRX) Financial ComparisonSeptember 29, 2026 | americanbankingnews.comPacira BioSciences (NASDAQ:PCRX) Stock Rating Raised to Strong-Buy at Wall Street ZenSeptember 26, 2026 | americanbankingnews.comOppenheimer Begins Coverage on Pacira BioSciences (NASDAQ:PCRX)September 25, 2026 | americanbankingnews.comOppenheimer initiates coverage of Pacira BioSciences with outperformSeptember 24, 2026 | msn.comOppenheimer Initiates Pacira Biosciences at Outperform With $32 Price TargetSeptember 23, 2026 | marketscreener.comMSee More Headlines PCRX Stock Analysis - Frequently Asked Questions How have PCRX shares performed this year? Pacira BioSciences' stock was trading at $25.88 on January 1st, 2026. Since then, PCRX shares have decreased by 3.2% and is now trading at $25.05. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) released its earnings results on Tuesday, August, 4th. The company reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.08. The firm's revenue for the quarter was up 6.2% compared to the same quarter last year. Read the conference call transcript. When did Pacira BioSciences IPO? Pacira BioSciences (PCRX) raised $64 million in an initial public offering (IPO) on Wednesday, February 2nd 2011. The company issued 4,250,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/04/2026Today10/06/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PCRX's financial health is in the Green zone, according to TradeSmith. PCRX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees829Year Founded2006Price Target and Rating Average Price Target for Pacira BioSciences$30.14 High Price Target$38.00 Low Price Target$25.00 Potential Upside/Downside+22.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$0.35 Trailing P/E Ratio70.32 Forward P/E Ratio12.88 P/E GrowthN/ANet Income$7.03 million Net Margins1.96% Pretax Margin2.37% Return on Equity9.68% Return on Assets5.30% Debt Debt-to-Equity Ratio0.54 Current Ratio5.04 Quick Ratio3.94 Sales & Book Value Annual Sales$746.16 million Price / Sales1.31 Cash Flow$3.77 per share Price / Cash Flow6.53 Book Value$16.11 per share Price / Book1.53Miscellaneous Outstanding Shares39,862,000Free Float37,311,000Market Cap$980.96 million OptionableOptionable Beta0.25 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:PCRX) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises...Priority Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
